Britain's Oxford Biomedica (OXB.L) fell more than 24% on Friday after the cell and gene therapy manufacturer cut its 2026 revenue forecast, citing operational delays at a U.S. site and deferred client orders.
Here are some more details:
($1 = 0.7436 pounds)
(This story has been refiled to remove extraneous words from the dateline)
